MIRA Pharmaceuticals, Inc.

MIRA

Healthcare Drug Manufacturers General

EPS
+66.7%
Free cash flow
−50.8%

Quarter to June 2026, against a year earlier

0.57 0.03 +5.56%
Market cap
$22.7M
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
Net debt / EBITDA
1.1×
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Current Ratio

+8 more quarters

90.56 15.75 82.13 200.19
Net Debt/EBITDA
5.72 1.89 8.52 7.02
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(0.06) (0.05) (0.03) (0.03)
Book value per Share
0.39 0.44 0.22 0.19
Free Cash Flow
(1.10) (1.14) (1.20) (1.21)
Other line items

Show all line items

Columns are period end dates